HCW Biologics: Maxim Group adjusts target price to $8 from $30 after 1-for-6 reverse stock split
HCWB•Maxim Group lowered its target price for HCW Biologics to $8 from $30 to reflect a 1-for-6 reverse stock split.
Related News
Autonomix Medical wins Canadian patent for catheter-based transvascular nerve therapy platform
AMIX•
Aureus Greenway completes merger with defense tech firm Powerus, keeps Nasdaq ticker PUSA
PUSA•
Rivian deliveries hit record high as R2 rollout gains momentum
RIVN•
Cencora to report fourth-quarter fiscal 2026 results and host conference call
COR•
Freeport says Indonesia smelter restarts after 2025 Grasberg incident
FCX•